Boundless Bio Reports $23.7 Million Net Loss and Plans Merger with Serapha Bio

Boundless Bio, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $23.7 million for the quarter, compared to a loss of $15.7 million in the same period last year, marking a 50.9% increase in losses. For the first half of 2026, the net loss totaled $37.2 million, up from $31.4 million in the first half of 2025. The increase in losses was primarily attributed to higher general and administrative expenses, which rose to $10.4 million from $4.8 million year-over-year, largely due to severance costs and stock-based compensation related to a workforce reduction.

In terms of operational metrics, Boundless Bio's total operating expenses for the second quarter of 2026 reached $24.4 million, a 42.9% increase from $17.1 million in the prior year. Research and development expenses remained relatively stable, totaling $14.0 million compared to $12.2 million in the previous year. The company’s accumulated deficit as of June 30, 2026, stood at $296.9 million, reflecting its ongoing struggle to achieve profitability since its inception in 2018.

Strategically, Boundless Bio is undergoing a significant transformation, highlighted by its announced merger with Serapha Bio, Inc. on June 22, 2026. This merger is expected to close in the fourth quarter of 2026, pending stockholder approvals and other conditions. Following the merger, the combined entity plans to focus on advancing Serapha's investigational therapy for Alpha-1 Antitrypsin Deficiency, while discontinuing the development of Boundless Bio's existing ecDNA-directed therapeutic candidates. The merger will result in a substantial ownership shift, with Serapha's stockholders expected to own approximately 96.31% of the combined company.

In conjunction with the merger, Boundless Bio has implemented a workforce reduction of approximately 75%, incurring a charge of about $2.8 million in the second quarter. The company also terminated its long-term lease for its headquarters, incurring a $10 million payment to the landlord, which has contributed to its cash outflows. As of June 30, 2026, Boundless Bio reported cash, cash equivalents, and short-term investments totaling $72.6 million, which it believes will be sufficient to fund operations for at least the next twelve months, excluding the anticipated pre-closing cash dividend of approximately $44 to $48 million.

Looking ahead, Boundless Bio's future hinges on the successful completion of the merger with Serapha. If the merger does not proceed, the company may need to explore alternative funding options to support its ongoing operations and potential development of its ecDTx pipeline. The company has indicated that it will continue to assess its strategic options, including collaborations and financing opportunities, to navigate its financial challenges and operational restructuring.